

2021



Progetto Ematologia Romagna

Le vescicole extracellulari ed il
metabolismo energetico nella leucemia acuta mieloide


Dorian Forte, Ph.D.



Dorian Forte, Ph.D.

- Nothing to disclose


Of what remains... in AML



Acute Myeloid Leukemia (AML) is a heterogeneous disease characterized by the proliferation of clonal stem-cell like blasts in the bone marrow (BM).

- ✘ The presence of **leukemia stem cells (LSC)** has prognostic relevance as they are presumed to initiate the relapse.
- ✘ Measurable Residual Disease (MRD) is the assessment of the percentage of residual leukemia cells after chemotherapy

Snapshot on Normal and Leukemic Myeloid Hematopoietic Hierarchies: know (metabolically) your enemy!



HSCs differentiate into multipotent progenitors (**MPPs**)

MPP differentiates to a common myeloid progenitor (**CMP**)

MEP → megakaryocyte-erythroid progenitor (**MEP**)


GMP → granulocyte-macrophage progenitor (**GMP**)




HSCs, MPPs, and CMPs can all potentially become a leukemic stem cell (LSC)

Metabolic Features mirrored by Leukemic Stem Cells (LSCs)

(A) *de novo* LSCs
Metabolically inflexible, therapy sensitive



(B) R/R LSCs
Metabolically plastic, therapy resistant




Trends in Molecular Medicine

(ven+aza): combination of venetoclax, a B cell lymphoma2 (BCL-2) inhibitor, and azacitidine, a DNA methyltransferase inhibitor

Cell Metabolism

Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy

Graphical Abstract



Authors

Dorian Forte, María García-Fernández, Abel Sánchez-Aguilera, ..., Brian J. Huntly, Juerg Schwaller, Simón Méndez-Ferrer

Correspondence

j.schwaller@unibas.ch (J.S.), sm2116@cam.ac.uk (S.M.-F.)

In Brief



Forte et al. reveal that nestin⁺ bone marrow stromal cells directly contribute to leukemogenesis and chemotherapy resistance in an *in vivo* model of acute myeloid leukemia. Nestin⁺ BMSCs support leukemic stem cells through a dual mechanism of increased bioenergetic capacity through OXPHOS and TCA and glutathione-dependent antioxidant defense.

AML Cells Hijack Nestin⁺ Niche Cells to Promote Leukemogenesis

Nestin⁺ cells represent a rare stromal population

Nestin⁺ cells co-localize near HSCs


Nestin⁺ cells are required for HSC homing and maintenance




BMSCs Support Leukemic Blast Survival and Chemoresistance

In vitro


nestin –
MSC adherent




Survival




ROS




GSH




nestin+ Dsred+
mesospheres





Targeting BMSCs-induced Antioxidant Defense improves antileukemic chemotherapy in vivo




Chemo = “5+3” i.p. injections of cytarabine (100 mg/kg/day over 5 days) and doxorubicin (3 mg/kg/day over 3 days)




Buthionine sulfoximine (BSO) is a sulfoximine which reduces the levels of glutathione (GSH)



Mitochondrial Respiration using Seahorse Extracellular Flux (Agilent)



Mitochondria transferred
from **MitoTracker CMXRos red⁺ BMSCs**
in **GSH⁺ leukemic blasts**



OCR= Oxygen consumption rate

Cell Metabolism

Article


Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy

Highlights

- Nestin⁺ BMSCs support leukemogenesis and chemoresistance
- BMSCs support metabolic requirements of LSCs
- BMSCs provide LSCs with essential antioxidant defense from chemotherapy
- GSH and GSH peroxidases underlie BMSC-derived antioxidant AML protection

Forte et al. Cell Metabolism 2020



Mitochondrial uptake by leukemic cells results in augmented ATP production through increased oxidative phosphorylation (OXPHOS) and higher drug resistance



Trends in Cancer




Extracellular Vesicles (EVs) as carriers of complex intercellular information within the microenvironment



The most abundant type of EVs in circulation are platelet-derived extracellular vesicles

EVs may also be considered a promising tool for liquid biopsy in routine clinical practice

Extracellular vesicle crosstalk in the leukemic microenvironment




(A) EVs from AML blasts reduced differentiation potential;

(B) AML EVs reprogram MSCs and stromal cells;

(C) AML and MDS EVs promote the loss of HSPC supportive factors;

Extracellular Vesicles and Chemotherapy Resistance in the leukemic microenvironment



EV trafficking between AML cells transfers regulatory factors that induce resistance to chemotherapy

Prof. MICHELE CAVO

Giulia Corradi	Gianluca Cristiano
Valentina Pensato	Chiara Sartor
Marilena Ciciarello	Jacopo Nanni
Darina Ocadlikova	Sofia Fatica
Valentina Salvestrini	Letizia Zannoni
Antonio Curti	Cristina Papayannidis
	Stefania Paolini
	Martina Barone
Samantha Bruno	Lucia Catani
Simona Soverini	

Collaborators:

Roberto Maria Pellegrino (Università di Perugia)	Simón Mendéz-Ferrer (Università di Cambridge)
Francesco Fabbri (IRCCS Meldola)	Paolo Gallipoli (Barts Cancer Institute)

Prof. SANTE TURA

Policlinico S.Orsola-Malpighi



SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Ospedaliero - Universitaria di Bologna
IRCCS Istituto di ricovero e cura a carattere scientifico



ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA



CANCER
RESEARCH
UK

CAMBRIDGE
CENTRE

